Hosted on MSN9h
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...
FierceBiotech1d
Gilead taps German biotech Tubulis for solid tumor ADC development deal worth up to $465M
Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...
BioPharma Dive9h
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
pharmaphorum1d
Gilead looks beyond Trodelvy with Tubulis alliance
The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...
Gilead enters ADC option and license pact with Tubulis, sees dilution
Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...
STAT1d
Sanofi pours $1 billion into China for insulin plant
Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...
Gilead, Tubulis Partner To Develop ADC Candidate For Solid Tumor Target
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...
The Pharma Letter1d
Gilead boosts ADC portfolio via licensing deal with Tubulis
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...
pharmaphorum1y
BMS goes down the Tubulis route for cancer ADCs
Bristol-Myers Squibb has formed another alliance focusing on antibody-drug conjugates (ADCs) for solid tumours, paying German biotech Tubulis $22.75 million upfront to get access to its linker and ...